


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+4.16%
-0.88%
-6.48%
-3.96%
+11.82%
AQST
Aquestive Therapeutics
$3.34
Strengths

Earnings are forecast to grow

Upgraded on attractively valued
Technical Indicators

Hammer Pattern
AQST Price Performance
$5.63 (-40.67%)
$7.47 (-55.29%)
$3.98 (-16.08%)
$3.02 (+10.60%)
AQST has Extreme risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

High volatilty

AQST overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Below analyst estimate
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Price value has negative momentum
Activity
Activity
Future
Future

Earnings are forecast to grow
![]()
AQST Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
AQST Street Sentiment is bullish and have positive views on the near-term outlook
Average key support and resistance price levels
What is AQST current stock price?
What are AQST stock strengths?
What is AQST Risk Level?
What is AQST market cap and volume?
What is AQST current Stock IQ?
Should I buy AQST stock right now?
Is AQST a Strong Buy right now?
What does a 'Strong Buy' rating mean for AQST?
What does a 'Strong Sell' rating mean for AQST?
What factors influence AQST's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+4.16%
-0.88%
-6.48%
-3.96%
+11.82%
AQST
Aquestive Therapeutics
Current Price
$3.34
AQST Stock IQ
Stock Insights
Strengths

Earnings are forecast to grow

Upgraded on attractively valued
Technical Indicators

Hammer Pattern

AQST Price Performance
$5.63 (-40.67%)
$7.47 (-55.29%)
$3.98 (-16.08%)
$3.02 (+10.60%)
AQST Analysts Opinion
AQST Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Below analyst estimate
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Price value has negative momentum
Activity
Activity
Future
Future

Earnings are forecast to grow
![]()
AQST Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
AQST Street Sentiment is bullish and have positive views on the near-term outlook
AQST has Extreme risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

High volatilty

Average key support and resistance price levels
AQST Latest Analysis
Heres Why Aquestive Therapeutics (AQST) Is a Great Buy the Bottom Stock Now. Aquestive Therapeutics (AQST) appears to have found support after losing some value lately as indicated by the formation of a hammer chart. In addition to this technical chart pattern strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stocks potential for a turnaround in the near term.
Wed Jan 14, 2026
Down 37% in 4 Weeks Heres Why Aquestive Therapeutics (AQST) Looks Ripe for a Turnaround . Aquestive Therapeutics (AQST) is technically in oversold territory now so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Mon Jan 12, 2026
Aquestive Stock Slides After FDA Flags Issues With Allergy Drug Application. AQST) stock is trading lower on Friday with a session volume of 5.68 million compared to the average volume of 2.79 million as per .The company on Friday said the United States Food and Drug Administration (FDA) has identified deficiencies in Anaphylm’.s New Drug Application (NDA) that preclude discussion of labeling and post-marketing commitments at this time.Although the notification did not specify the deficienc
Fri Jan 9, 2026
Aquestive drops as FDA flags issues in Anaphylm marketing application.
Fri Jan 9, 2026
Aquestive Therapeutics (AQST) Upgraded to Buy: Heres Why. Aquestive Therapeutics (AQST) has been upgraded to a Zacks Rank #2 (Buy) reflecting growing optimism about the companys earnings prospects. This might drive the stock higher in the near term.
Wed Jan 7, 2026
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
AQST Stock trends
AQST Stock performance
AQST Stock analysis
AQST investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.